© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gynecologic Cancers
FDA Approves cobas HPV Test for Measurement of Cervical Cancer Risk in Women with High-Risk HPV
April 21, 2020
"The approval of our HPV test for the cobas 6800 and 8800 Systems enables molecular laboratories to achieve the efficiency and scale they need to meet the demands of high-volume cervical screening programs..."
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
April 17, 2020
Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival over chemotherapy.
Niraparib Grabs Regulatory Attention in China for Treatment of Advanced Ovarian Cancer
April 16, 2020
Niraparib was granted Priority Review in China as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, by the National Medical Products Administration.
A 59-Year Old Woman With Stage IIIC Ovarian Cancer
April 15, 2020
A 59-Year Old Woman With Stage IIIC Ovarian Cancer
Veliparib Spotlighted for Antitumor Efficacy in Ovarian Cancer
April 15, 2020
In the phase III VELIA trial, the addition of veliparib to frontline induction chemotherapy expanded the number of complete responses and CA-125 responses in patients with high-grade serous ovarian cancer compared with chemotherapy alone, according to results from an exploratory analysis.
Vigil Immunotherapy Prolongs RFS as Frontline Maintenance Treatment in Ovarian Cancer
April 14, 2020
Relapse-free survival was prolonged in patients with stage III/IV ovarian cancer who received frontline maintenance treatment with Vigil immunotherapy compared with placebo. This was especially true for patients with BRCA1/2 wild-type disease, according to results from the phase II VITAL study.
Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity
April 13, 2020
Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II OVARIO trial.
Analyses of Frontline Niraparib Maintenance Demonstrate Positive Patient-Reported Outcomes in Ovarian Cancer
April 11, 2020
Following its success in the phase III PRIMA study, frontline niraparib maintenance demonstrated positive patient-reported outcomes, as well as met biomarker-defined and other secondary endpoints, according to 3 analyses to be reported as part of the Society of Gynecologic Oncology 2020 Annual Meeting.
FDA Grants Fast Track Designation to Balstilimab in Metastatic Cervical Cancer
April 08, 2020
The FDA has granted Fast Track designation to balstilimab, an investigational anti-PD-1 agent for the treatment of patients with cervical cancer, based on comprehensive data that suggest balstilimab can fill an unmet medical need in the space, Agenus, Inc announced in a press release. In light of the new designation, the company now plans to submit 2 Biologic License Applications in 2020, for this indication and the other for the combination of balstilimab and zalifrelimab in metastatic cervical cancer.